Ultralife SEC Filings

Ultralife Corp director Janie Goddard reported buying 1,739 shares of the company's common stock on 12/15/2025 at a price of $5.75 per share, according to a Form 4 insider filing.

After this purchase, she beneficially owns 7,668 Ultralife shares held directly.

Ultralife Corp (ULBI) director share purchase reported. A company director filed a Form 4 disclosing the open-market purchase of 1,750 shares of Ultralife Corp common stock on 11/24/2025 at a price of $5.67 per share. Following this transaction, the director now beneficially owns 71,000 shares held directly. The filing notes the transaction as a purchase of non-derivative common stock and indicates it was reported by a single reporting person.

Ultralife Corp (ULBI) director and 10% owner Bradford T. Whitmore reported an open-market purchase of 53,900 shares of common stock on 11/19/2025 at a weighted average price of $4.9706 per share through Whitmore Holdings, LLC.

After this transaction, he beneficially owned 1,182,631 shares indirectly through Whitmore Holdings, 205,915 shares directly, 4,452,283 shares indirectly through Sunray I, LLC, and 518,616 shares indirectly through Grace Brothers, LP. The price range for the individual trades that made up the purchase was from $4.9425 to $5.05 per share.

Ultralife Corporation (ULBI) reported an insider share purchase by its President and CEO, who is also a director. On 11/19/2025, the executive bought a total of 2,000 shares of common stock in two open-market transactions. The purchases were made at prices of $4.943 and $4.99 per share, increasing the executive’s direct beneficial ownership to 24,874 shares after the transactions. This filing reflects the executive’s personal investment activity in Ultralife stock.

Ultralife Corporation filed a current report to announce that it has released financial results for its third quarter ended September 30, 2025. The company states that these results are presented in a press release dated November 18, 2025, which is attached as Exhibit 99.1. The filing is signed by the Chief Financial Officer and Treasurer, highlighting that this is the formal disclosure of the latest quarterly performance details through the accompanying press release.

Ultralife Corporation reported higher sales but lower profitability for the quarter ended September 30, 2025. Revenue rose to $43,371 from $35,694, driven mainly by Battery & Energy Products and the contribution from the October 2024 Electrochem acquisition. Gross margin slipped to 22.2% from 24.3%, reflecting less favorable product mix, component quality issues and lower factory throughput, leading to an operating loss of $951 and a net loss attributable to Ultralife of $1,220 versus net income of $258 a year earlier.

For the first nine months of 2025, revenue increased to $142,678 from $120,604, while net income attributable to Ultralife declined to $1,524 from $6,118, as higher interest expense and integration and restructuring costs weighed on results. Electrochem, acquired for $48,022 in cash, contributed nine‑month revenue of $23,718. To fund the deal, Ultralife entered a new credit agreement including a five‑year $55,000 term loan, with $50,937 outstanding at a 6.62% borrowing rate and all debt covenants met. Operating cash flow remained solid at $9,501, lifting cash to $9,260.

Ultralife Corporation filed a Form 12b-25 (NT 10-Q) notifying a late filing for its quarterly report for the period ended September 30, 2025. The company cites its integration of Electrochem Solutions, Inc.—acquired from Integer Holdings on October 31, 2024—as the cause, noting that Electrochem’s books and records transitioned from Integer’s systems to Ultralife’s during the third quarter of 2025.

Ultralife states it needs additional time to finalize third quarter results and allow its independent accountants to complete their review without unreasonable effort or expense. The company expects to file the Form 10-Q within the five-day extension under Rule 12b-25, no later than November 17, 2025.

Ultralife Corporation replaced its independent auditor on August 22, 2025, when the Audit and Finance Committee approved ending the engagement with Freed Maxick P.C. and engaged Withum Smith+Brown, PC effective immediately due to Withum's acquisition of certain assets of Freed Maxick. Freed Maxick's audit reports for the years ended December 31, 2023 and December 31, 2024 contained no qualifications on the company’s financial statements, but its report on internal control over financial reporting for 2024 stated the company did not maintain effective internal control because of a material weakness. The company reported no disagreements or reportable events with Freed Maxick for the reviewed periods and furnished Freed Maxick a copy of this disclosure; Freed Maxick provided a letter dated August 25, 2025 responding to the disclosure.

Bradford T. Whitmore, a director and 10% owner of Ultralife Corporation (ULBI), reported several open-market transactions on Form 4. Between 08/19/2025 and 08/21/2025 he purchased 58,664 shares in multiple trades at weighted average prices of about $6.56–$6.63 per share. After those purchases, Whitmore Holdings, LLC beneficially owned 1,128,731 shares indirectly. The filing also records a disposition of 205,915 shares and discloses larger indirect holdings: 4,452,283 shares via Sunray I, LLC and 518,616 shares via Grace Brothers, LP. Explanatory footnotes state the purchase prices are weighted averages and clarify Whitmore's indirect ownership through his managerial and trustee roles.